Is Australia positioned to take advantage of biosimilars?
Lim, David (2014) Is Australia positioned to take advantage of biosimilars? Generics and Biosimilars Initiative Journal, 3(4), pp. 184-187.
Australia currently has a small generic and biosimilar industry despite having a good track record in biomedical research and a sound reputation in producing high quality but small volume biological pharmaceuticals. In recent times, Australia has made incremental changes to its regulation of biosimilars – in patent registration, in the use of commercial confidential information, and in remuneration. These improvements, together with Australia’s geographical proximity and strong trade relationship with the Asian biocluster have positioned Australia to take advantage of potential public cost savings from the increased use of biosimilars.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Biosimilars, Australia, Regulation, Policy, Intellectural property, Patent, Confidential information, Governance, Pharmaceutical Benefits Scheme, Pharmaceutical, Quality use of medicines|
|Divisions:||Current > Schools > School of Clinical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2014 Pro Pharma Communications International|
|Deposited On:||22 Jan 2015 02:06|
|Last Modified:||07 Oct 2016 01:58|
Repository Staff Only: item control page